Literature DB >> 29768704

Syntheses and Immunological Evaluation of Self-Adjuvanting Clustered N-Acetyl and N-Propionyl Sialyl-Tn Combined with a T-helper Cell Epitope as Antitumor Vaccine Candidates.

Tsung-Che Chang1, Yoshiyuki Manabe1,2, Yukari Fujimoto3, Shino Ohshima4, Yoshie Kametani4, Kazuya Kabayama1,2, Yuka Nimura1, Chun-Cheng Lin5, Koichi Fukase1,2.   

Abstract

Sialyl-Tn (STn) is a tumor-associated carbohydrate antigen (TACA) rarely observed on healthy tissues. We synthesized two fully synthetic N-acetyl and N-propionyl STn trimer (triSTn) vaccines possessing a T-helper epitope and a TLR2 agonist, since the clustered STn antigens are highly expressed on many cancer cells. Immunization of both vaccines in mice induced the anti-triSTn IgG antibodies, which recognized triSTn-expressing cell lines PANC-1 and HepG2. The N-propionyl triSTn vaccine induced the triSTn-specific IgGs, while IgGs induced by the N-acetyl triSTn vaccine were less specific. These results illustrated that N-propionyl triSTn is a valuable unnatural TACA for anticancer vaccines.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  adjuvants; antigens; cancer vaccines; carbohydrates; sialyl-Tn

Mesh:

Substances:

Year:  2018        PMID: 29768704     DOI: 10.1002/anie.201804437

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  6 in total

1.  Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.

Authors:  Mingjing Li; Zhaoyu Wang; Bocheng Yan; Xiaona Yin; Yue Zhao; Fan Yu; Meng Meng; Yonghui Liu; Wei Zhao
Journal:  Medchemcomm       Date:  2019-07-12       Impact factor: 3.597

2.  Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response.

Authors:  Chengcheng Song; Xiu-Jing Zheng; Haili Guo; Yafei Cao; Fan Zhang; Qin Li; Xin-Shan Ye; Yifa Zhou
Journal:  Glycoconj J       Date:  2019-07-02       Impact factor: 2.916

3.  Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope.

Authors:  Tsung-Che Chang; Yoshiyuki Manabe; Keita Ito; Ryuku Yamamoto; Kazuya Kabayama; Shino Ohshima; Yoshie Kametani; Yukari Fujimoto; Chun-Cheng Lin; Koichi Fukase
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

4.  Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development.

Authors:  Xiang Luo; Qinghai Lian; Wenwei Li; Liqing Chen; Renyu Zhang; Deying Yang; Lingqiang Gao; Xiaoxiao Qi; Zhongqiu Liu; Guochao Liao
Journal:  Chem Sci       Date:  2021-12-01       Impact factor: 9.825

5.  Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.

Authors:  Qi Feng; Xiaoyue Yu; Yixue Wang; Shiyang Li; Yang Yang
Journal:  RSC Adv       Date:  2021-10-15       Impact factor: 3.361

Review 6.  Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine.

Authors:  Yuna Guo; Wenshuang Jia; Jingru Yang; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-22       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.